Start with the right security.
Names and tickers can change. A useful review begins with the instrument, its identifiers and the relevant period, not a ticker in isolation.
BlueLedger is being developed around one connected workflow: follow a security, compare its records, inspect the evidence and preserve what the review establishes, including what remains unresolved.
Product development is underway. Available access and coverage must be confirmed for each evaluation.
Names and tickers can change. A useful review begins with the instrument, its identifiers and the relevant period, not a ticker in isolation.
The planned reconciliation workspace brings Expected, Detected and Gap together. Its purpose is to show which records can be compared, where they agree and which differences need further review.
BlueLedger is being shaped around issuer questions, with records, dates and limitations in view for management, boards and professional advisers.
For issuersThe product is being designed to keep source references, dates, relationships and limitations alongside each finding. An observation should remain distinguishable from an interpretation.
Evidence Dossiers are the planned home for selected records, review notes and unresolved questions. A dossier is the working review; an evidence package is a prepared export. Neither label guarantees acceptance by a court or regulator.
AI assistance is being developed to help explain records and organize review questions. Sources, limitations and human judgment remain essential.
We're developing an individual-investor pathway alongside issuer and professional workflows. We're exploring a free starting option and paid features. The feature set, coverage and pricing are not yet finalized.
Explore retail accessCoverage depends on the security, available sources, permissions and the release. An evaluation does not by itself verify issuer authority or activate live monitoring.
Get help setting up issuer coverage